Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omnitram vs Tramadol PK, Safety, and Analgesia in Healthy Subjects
NCT02205554Phase 1Completed
- Sponsor
- Syntrix Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of desmetramadol in pain (3 arms), sponsored by Syntrix Pharmaceuticals. Primary endpoints: Omnitram and Tramadol Steady State Maximum and Minimum Concentrations at 4.0 hours and Adverse events at 29 days. Started Aug 2014; status: completed.
02
Drugs
desmetramadol
03
Conditions
pain
Beyond the preview
Go deeper on NCT02205554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205554.